- ►annals.org [PDF] DM Arnold, F Dentali, MA Crowther, RM Meyer … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Rituximab, a monoclonal anti-CD20 antibody, is in- creasingly used
to treat idiopathic thrombocytopenic purpura (ITP). ... Purpose: To
systematically review the literature on the efficacy and safety of ... Cited by 137 - Related articles - BL Direct - All 3 versions
- ►hematologylibrary.org K Kojouri, SK Vesely, DR Terrell, JN George - Blood, 2004 - bloodjournal.hematologylibrary.org Splenectomy was the primary treatment for idiopathic (immune) thrombocytopenic
purpura (ITP) prior to the introduction of glucocorticoids more than 50 years
ago. 1 For the past 50 years, splenectomy has remained a standard treatment ... Cited by 145 - Related articles - BL Direct - All 9 versions
- ►cancercaresouthtexas.com [PDF] JB Bussel, DJ Kuter, JN George, R McMillan, … - The New England journal of medicine, 2006 - nejm.highwire.org Results No major adverse events that could be attributed directly to AMG 531
occurred during the treatment period; 4 of 41 patients had transient
post-treatment worsening of thrombocytopenia. In phase 1, a platelet count ... Cited by 175 - Related articles - BL Direct - All 14 versions
A Newland, MT Caulier, M Kappers-Klunne, MR … - British journal of haematology, 2006 - interscience.wiley.com The objective of this open label, phase 1–2, multicentre trial was to evaluate
the safety of AMG 531, a novel thrombopoiesis-stimulating peptibody, and its
effect on platelet counts in adults with immune thrombocytopenic purpura. ... Cited by 76 - Related articles - BL Direct - All 6 versions
N Cooper, R Stasi, S Cunningham-Rundles, … - British journal of haematology, 2004 - interscience.wiley.com Because of its B-cell depleting effect, rituximab has entered clinical trials in
several autoimmune conditions. This study assesses the efficacy and safety of
rituximab in 57 adults with chronic immune thrombocytopenic purpura (ITP). ... Cited by 179 - Related articles - BL Direct - All 5 versions
- ►farmacologiaenred.com.ar [PDF] JB Bussel, G Cheng, MN Saleh, B Psaila, L … - The New England Journal of Medicine, 2007 - nejm.highwire.org Results In the eltrombopag groups receiving 30, 50, and 75 mg per day, the
primary end point was achieved in 28%, 70%, and 81% of patients, respectively.
In the placebo group, the end point was achieved in 11% of patients. The ... Cited by 122 - Related articles - BL Direct - All 5 versions
- ►cancercaresouthtexas.com [PDF] DJ Kuter, JB Bussel, RM Lyons, V Pullarkat, … - The Lancet, 2008 - Elsevier In two parallel trials, 63 splenectomised and 62 non-splenectomised patients
with ITP and a mean of three platelet counts 30×10 9 /L or less were randomly
assigned 2:1 to subcutaneous injections of romiplostim (n=42 in ... Cited by 114 - Related articles - All 44 versions
- ►annals.org [PDF] SK Vesely, JJ Perdue, MA Rizvi, DR Terrell, … - Annals of internal medicine, 2004 - Am Coll Physicians Background: Treatment of chronic refractory idiopathic throm- bocytopenic
purpura is a dilemma because many patients have minimal symptoms, response to
treatment is uncertain, and treat- ments may have serious adverse effects. ... Cited by 79 - Related articles - All 7 versions
DB Cines, JB Bussel - Blood, 2005 - bloodjournal.hematologylibrary.org Until recently, experience from numerous centers over more than a half-century
indicated that the typical adult with ITP is a woman, generally between 18 and
40 years of age. 6 Gender disparity largely disappears among the elderly. ... Cited by 115 - Related articles - BL Direct - All 9 versions
JN George - Journal of Thrombosis and Haemostasis, 2006 - w3.ouhsc.edu Summary. In immune thrombocytopenic purpura (ITP), thrombocytopenia is a result
of both increased platelet destruction and insufficient platelet production. In
adults, the course is commonly chronic, but most patients never experience ... Cited by 65 - Related articles - View as HTML - BL Direct - All 6 versions
